Characterization of the role of IL-6 in the progression of prostate cancer

Prostate

Volumn 38, Issue 3, 1999, Pages 199-207

  Chung, Theodore D K ^a,c   Yu, Jianqing J ^a   Spiotto, Michael T ^a   Bartkowski, Michelle ^b   Simons, Jonathan W ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cytokines; Hormone resistance; IL 6; IL 6 receptor; Prostate cancer

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; GLYCOPROTEIN GP 130; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; NEUTRALIZING ANTIBODY; ONCOSTATIN M; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE DEPENDENCE; HORMONE RESISTANCE; HUMAN; HUMAN CELL; LIGAND BINDING; MULTIGENE FAMILY; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

CELL DIVISION; CILIARY NEUROTROPHIC FACTOR; DISEASE PROGRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; GROWTH INHIBITORS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOKINES; MALE; MULTIGENE FAMILY; NERVE TISSUE PROTEINS; ONCOSTATIN M; PEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033557246     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H     Document Type: Article

References (44)

1. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
2. Isaacs JT, Schulze H, Coffey DS. Development of androgen resistance in prostatic cancer. Prog Clin Biol Res 1987;243:21-31.
3. Barrack ER, Tindall DJ. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 1987;239:155-187.
4. Ruizeveld-de-Winter JA, Trapman J, Brinkmann AO, Boersma WJ, Schroeder ME, Claassen E, Van-der-Kwast TH. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunocytochemistry. J Pathol 1990;161:329-332.
5. Knabbe C, Kellner U, Schmahl M, Voigt KD. Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J Steroid Biochem Mol Biol 1991;40:185-192.
6. Hirano T, Kishimoto T. Interleukins: molecular biology and immunology. In: Kishimoto T, ed. Chemical immunology. Basel: Karger; 1992. p 153-180.
7. Miki S, Iwano M, Miki Y, Yamamoto M, Tang T, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-610.
8. Miles SA, Rezai AR, Salazar-Gonzalez JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O. AIDS-Kaposi's sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;40:4068-4072.
9. Yee C, Biondi A, Wang HH, Iscove NN, de Sousa J, Aarde LA, Wong GG, Clark SD, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989;74:798-804.
10. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
11. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 1996;2:215-221.
12. Taga T, Kawanishi K, Hardy RR, Hirano T, Kishimoto TJ. Receptors for B cell stimulatory factor 2: quantitation, specificity, distribution and regulation of their expression. J Exp Med 1987; 166:956-981.
13. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanish Y, Seed B, Tanaguchi T, Hirano T, Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN 2) receptor. Science 1988; 241:825-828.
14. Siegall CB, Nordan RP, FitzGerald DJ, Pastan I. Cell-specific cytotoxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol Cell Biol 1990;10:2443-2447.
15. Siegsmund MJ, Yamazaki H, Pastan II. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396-1399.
16. Twillie DA, Eisertbserger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin 6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-549.
17. Chomeznski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1989.
19. Boulton TG, Stahl N, Yancopoulos GD. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces ryrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J Biol Chem 1994;269:11648-11655.
20. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-597.
21. Nelson KA, Walsh D, Sheehan F. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-225.
22. Lang SH, Miller WR, Duncan W, Habib FK. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. Int J Cancer 1995;59:235-241.
23. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
24. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995;95:2886-2895.
25. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991;88:7605-7609.
26. Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wildtype p53 mediates positive regulation of gene expression through specific DNA sequence elements. Genes Dev 1992;6: 1143-1152.
27. Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol 1992; 148:4055-4071.
28. Revel M. Antitumor potentials of interleukin 6. Interferons Cytokines 1991;19:5-8.
29. Kooistra A, Konig JJ, Keizer DM, Romign IC, Schroder FH. Inhibition of prostatic epithelial cell proliferation by a factor secreted specifically be prostate stromal cells. Prostate 1995;26: 123-132.
30. DeGeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak M-P, Millot G, DeCremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68:207-214.
31. Serve H, Steinhauser G, Oberberg D, Flegel WA, Northoff H, Berdel WE. Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines. Cancer Res 1991; 51:3862-3866.
32. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1291-1288.
33. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994;263: 89-92.
34. Stahl N, Yancopoulos GD. The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. J Neurobiol 1994;25:1454-1466.
35. Steiner ML, Barrack ER. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
36. Matuo Y, Nishi N, Wada F. Growth factors in the prostate. Arch Androl 1987;19:193-210.
37. Mansson PE, Adams P, Kan M, McKeehan WL. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989;49:2485-2494.
38. Shain SA, Ke LD, Wong G, Karaganis AG. Rat prostate cancer cell-line production and apparent secretion of heparin-binding growth factors. Cell Growth Differ 1992;3:249-258.
39. Sehgal I, Bailey J, Hitzemann K, Pittelkow MR, Maihle NJ. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol Biol Cell 1994;5:339-347.
40. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-met) in prostatic carcinoma. Am J Pathol 1995;147:386-396.
41. Tamm I, Cardinale I, Murphy JS. Decreased adherence of interleukin 6-treated breast carcinoma cells can lead to separation from neighbors after mitosis. Proc Natl Acad Sci USA 1991;88: 4414-4418.
42. Kirnbauer R, Charvat B, Schauer E, Kock A, Urbanshi A, Forster E, Neuner P, Ausmann I, Luger TA, Schwarz T. Modulation of intercellular adhesion molecule 1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL6, IL7, TNF beta and UVB light. J Invest Dermatol 1992;98: 320-326.
43. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller BG. De novo expression of intercellular adhesion molecule 1 in melanoma correlates with increase risk of metastasis. Proc Natl Acad Sci USA 1989;86:641-644.
44. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-4639.